226 related articles for article (PubMed ID: 12512696)
1. No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors.
Chlopicki S; Kozlovski VI; Gryglewski RJ
J Physiol Pharmacol; 2002 Dec; 53(4 Pt 1):615-24. PubMed ID: 12512696
[TBL] [Abstract][Full Text] [Related]
2. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
[TBL] [Abstract][Full Text] [Related]
3. Nebivovol and carvedilol induce NO-dependent coronary vasodilatation that is unlikely to be mediated by extracellular ATP in the isolated guinea pig heart.
Kozlovski VI; Lomnicka M; Chlopicki S
Pharmacol Rep; 2006; 58 Suppl():103-10. PubMed ID: 17332679
[TBL] [Abstract][Full Text] [Related]
4. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization.
Dessy C; Moniotte S; Ghisdal P; Havaux X; Noirhomme P; Balligand JL
Circulation; 2004 Aug; 110(8):948-54. PubMed ID: 15302798
[TBL] [Abstract][Full Text] [Related]
5. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism.
Cockcroft JR; Chowienczyk PJ; Brett SE; Chen CP; Dupont AG; Van Nueten L; Wooding SJ; Ritter JM
J Pharmacol Exp Ther; 1995 Sep; 274(3):1067-71. PubMed ID: 7562470
[TBL] [Abstract][Full Text] [Related]
6. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
[TBL] [Abstract][Full Text] [Related]
7. Clonidine-induced coronary vasodilatation in isolated guinea pig heart is not mediated by endothelial alpha2 adrenoceptors.
Chlopicki S; Kozlovski VI; Gryglewski RJ
J Physiol Pharmacol; 2003 Dec; 54(4):511-21. PubMed ID: 14726607
[TBL] [Abstract][Full Text] [Related]
8. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
Gupta S; Wright HM
Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
[TBL] [Abstract][Full Text] [Related]
9. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
Brodde OE; Philipp T
Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
[TBL] [Abstract][Full Text] [Related]
10. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery.
Georgescu A; Pluteanu F; Flonta ML; Badila E; Dorobantu M; Popov D
Eur J Pharmacol; 2005 Jan; 508(1-3):159-66. PubMed ID: 15680267
[TBL] [Abstract][Full Text] [Related]
11. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
Prisant LM
J Clin Pharmacol; 2008 Feb; 48(2):225-39. PubMed ID: 18083889
[TBL] [Abstract][Full Text] [Related]
12. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
Ignarro LJ
Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the different adrenoceptor targets of nebivolol enantiomers in rat thoracic aorta.
Tran Quang T; Rozec B; Audigane L; Gauthier C
Br J Pharmacol; 2009 Feb; 156(4):601-8. PubMed ID: 19210511
[TBL] [Abstract][Full Text] [Related]
14. Mixed beta3-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta.
Rozec B; Quang TT; Noireaud J; Gauthier C
Br J Pharmacol; 2006 Apr; 147(7):699-706. PubMed ID: 16474420
[TBL] [Abstract][Full Text] [Related]
15. Anti-thrombotic effects of nebivolol and carvedilol: Involvement of β2 receptors and COX-2/PGI2 pathways.
Kozlovski VI; Lomnicka M; Bartus M; Sternak M; Chlopicki S
Pharmacol Rep; 2015 Oct; 67(5):1041-7. PubMed ID: 26398401
[TBL] [Abstract][Full Text] [Related]
16. Characterization of nitric oxide release by nebivolol and its metabolites.
Maffei A; Vecchione C; Aretini A; Poulet R; Bettarini U; Gentile MT; Cifelli G; Lembo G
Am J Hypertens; 2006 Jun; 19(6):579-86. PubMed ID: 16733229
[TBL] [Abstract][Full Text] [Related]
17. Nebivolol: endothelium-mediated vasodilating effect.
Ritter JM
J Cardiovasc Pharmacol; 2001 Dec; 38 Suppl 3():S13-6. PubMed ID: 11811387
[TBL] [Abstract][Full Text] [Related]
18. Nebivolol induces a hyperpolarizing effect on smooth muscle cells in the mouse renal artery by activation of beta-2-adrenoceptors.
Georgescu A; Pluteanu F; Flonta ML; Badila E; Dorobantu M; Popov D
Pharmacology; 2008; 81(2):110-7. PubMed ID: 17952013
[TBL] [Abstract][Full Text] [Related]
19. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker.
Ignarro LJ
Blood Press Suppl; 2004 Oct; 1():2-16. PubMed ID: 15587107
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells.
Ladage D; Brixius K; Hoyer H; Steingen C; Wesseling A; Malan D; Bloch W; Schwinger RH
Clin Exp Pharmacol Physiol; 2006 Aug; 33(8):720-4. PubMed ID: 16895546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
